ReviewOncology letters2025

Patients with non‑small cell lung cancer with the exon 21 L858R mutation: From distinct mechanisms to epidermal growth factor receptor tyrosine kinase inhibitor treatments (Review).

Jia-Yu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.